Advertisement

Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens

  • S. R. Scriver
  • B. M. Willey
  • D. E. Low
  • A. E. Simor
New Antimicrobial Agents

Abstract

The in vitro activity of cefdinir (CI-983; FK-482), a new oral cephalosporin, was compared with that of other antimicrobial agents against clinical isolates of staphylocci, gram-negative bacilli and common respiratory tract pathogens. Cefdinir (MIC90 ≤ 2.0 µg/ml) was more active than cefixime (MIC90 >64 µg/ml) and equally as active as cefuroxime (MIC90 2.0 µg/ml) against oxacillin-susceptible staphylococci. Cefdinir was active againstHaemophilus influenzae, including β-lactamase producers (MIC90 0.5 µg/ml),Moraxella catarrhalis (MIC90 ≤ 0.12 µg/ml),Streptococcus pneumoniae (MIC90 ≤ 0.06 µg/ml) andStreptococcus pyogenes (MIC90 ≤ 0.06 µg/ml). The activity of cefdinir against gram-negative bacilli was variable; organisms with chromosomal cephalosporinases were often resistant.

Keywords

Internal Medicine Respiratory Tract Antimicrobial Agent Cephalosporin Clinical Isolate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A2. NCCLS, Villanova, PA, 1990.Google Scholar
  2. 2.
    Inamoto Y, Chiba T, Kamimura T, Takaya T: FK482, a new orally active cephalosporin. Synthesis and biological properties. Journal of Antibiotics 1988, 41: 828–830.Google Scholar
  3. 3.
    Sakamoto H, Hirose T, Nakamoto S, Hatano K, Shibayama F, Kikuchi H, Mine Y: Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. Journal of Antibiotics 1988, 41: 1896–1905.Google Scholar
  4. 4.
    Mine Y, Kamimura T, Watanabe Y, Tawara S, Matsumoto Y, Shibayama F, Kikuchi H, Takaya T: In vitro antibacterial activity of FK482, a new orally active cephalosporin. Journal of Antibiotics 1988, 41: 1873–1889.Google Scholar
  5. 5.
    Neu HC, Saha G, Chin NX: Comparative in vitro activity and β-lactamase stability of FK482, a new oral cephalosporin. Antimicrobial Agents and Chemotherapy 1989, 33: 1795–1800.Google Scholar
  6. 6.
    Briggs BM, Jones RN, Gruin ME, Barrett MS, Johnson DM: In vitro activity evaluations of cefdinir (FK482, CI-983 and PD134393): a novel orally administered cephalosporin. Diagnostic Microbiology and Infectious Diseases 1991, 14: 425–434.Google Scholar
  7. 7.
    Wise R, Andrews JM, Thornber D: The in vitro activity of cefdinir (FK482), a new oral cephalosporin. Journal of Antimicrobial Chemotherapy 1991, 28: 239–248.Google Scholar

Copyright information

© Friedr, Vieweg & Sohn Verlagsgesellschaft mbH 1992

Authors and Affiliations

  • S. R. Scriver
    • 1
  • B. M. Willey
    • 1
  • D. E. Low
    • 1
  • A. E. Simor
    • 1
  1. 1.Department of Microbiology, Mount Sinai HospitalUniversity of TorontoTorontoCanada

Personalised recommendations